Primene 10% Solution for Infusion Ирландия - английски - HPRA (Health Products Regulatory Authority)

primene 10% solution for infusion

baxter holding b.v. - l-isoleucine; l-leucine; l-valine; l-lysine; l-methionine; l-threonine; l-tryptophan; l-arginine; l-histidine; l-alanine; l-aspartic acid; cysteine; l-glutamic acid; glycine; l-proline; l-serine; l-tyrosine; ornithine hydrochloride; taurine; l-phenylalanine - solution for infusion - 10 percent - solutions for parenteral nutrition; amino acids

Potassium Chloride 0.3% w/v and Glucose 5% w/v Solution for Infusion Ирландия - английски - HPRA (Health Products Regulatory Authority)

potassium chloride 0.3% w/v and glucose 5% w/v solution for infusion

b. braun melsungen ag - potassium chloride; glucose monohydrate - solution for infusion - 0.3%w/v + 5.0 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates

Potassium Chloride 0.15% w/v and Glucose 5% w/v solution for infusion Ирландия - английски - HPRA (Health Products Regulatory Authority)

potassium chloride 0.15% w/v and glucose 5% w/v solution for infusion

b. braun melsungen ag - potassium chloride; glucose monohydrate - solution for infusion - 0.15%w/v +5.0 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates

Plasma-Lyte 148 (ph 7.4) Solution for Infusion (500ml) Малта - английски - Medicines Authority

plasma-lyte 148 (ph 7.4) solution for infusion (500ml)

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - sodium chloride, potassium chloride, magnesium chloride, hexahydrate, sodium acetate, trihydrate, sodium gluconate - solution for infusion - sodium chloride 5.26 g/l potassium chloride 0.37 g/l magnesium chloride hexahydrate 0.30 g/l sodium acetate trihydrate 3.68 g/l sodium gluconate 5.02 g/l - blood substitutes and perfusion solutions

Plasma-Lyte 148 (ph 7.4) Solution for Infusion (1000ml) Малта - английски - Medicines Authority

plasma-lyte 148 (ph 7.4) solution for infusion (1000ml)

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - sodium chloride, potassium chloride, magnesium chloride, hexahydrate, sodium acetate, trihydrate, sodium gluconate - solution for infusion - potassium chloride 0.37 g/l magnesium chloride hexahydrate 0.30 g/l sodium acetate trihydrate 3.68 g/l sodium gluconate 5.02 g/l sodium chloride 5.26 g/l - blood substitutes and perfusion solutions

Maintelyte Solution for Infusion Малта - английски - Medicines Authority

maintelyte solution for infusion

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - glucose anhydrous, sodium chloride, sodium acetate, trihydrate, potassium chloride, magnesium chloride, hexahydrate - solution for infusion - glucose anhydrous 50 g sodium chloride 1 g sodium acetate trihydrate 3.13 g potassium chloride 1.5 g magnesium chloride hexahydrate 0.30 g - blood substitutes and perfusion solutions

Ceftriaxone PharmSol 1000 mg Powder for Solution for Injection/Infusion Малта - английски - Medicines Authority

ceftriaxone pharmsol 1000 mg powder for solution for injection/infusion

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftriaxone - powder for solution for injection/infusion - ceftriaxone 1000 mg - antibacterials for systemic use

LIBTAYO cemiplimab 350 mg concentrate for solution for infusion Австралия - английски - Department of Health (Therapeutic Goods Administration)

libtayo cemiplimab 350 mg concentrate for solution for infusion

sanofi-aventis australia pty ltd - cemiplimab, quantity: 350 mg - injection, intravenous infusion - excipient ingredients: sucrose; histidine; histidine hydrochloride monohydrate; water for injections; proline; polysorbate 80 - cutaneous squamous cell carcinoma,libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. non-small cell lung cancer,libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 tumour proportion score (tps) greater than and equal to 50% as determined by a validated test, with no egfr, alk or ros1 aberrations, who have:,? locally advanced nsclc and who are not candidates for surgical resection or definitive chemoradiation, or ? metastatic nsclc.,libtayo in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with nsclc whose tumours have no egfr, alk or ros1 aberrations and is:,? locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or,? metastatic. basal cell carcinoma,libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (bcc) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.

Micafungin Sandoz 50 mg powder for concentrate for solution for infusion Малта - английски - Medicines Authority

micafungin sandoz 50 mg powder for concentrate for solution for infusion

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - micafungin sodium - powder for concentrate for solution for infusion - micafungin sodium 50 mg - antimycotics for systemic use

Micafungin Sandoz 100 mg powder for concentrate for solution for infusion Малта - английски - Medicines Authority

micafungin sandoz 100 mg powder for concentrate for solution for infusion

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - micafungin sodium - powder for concentrate for solution for infusion - micafungin sodium 100 mg - antimycotics for systemic use